Fig. 4

Treatment with NTP42 attenuates MCT-induced pulmonary vascular remodelling. Detailed morphometric analysis was performed as outlined in the Supplementary Material. Panels a-c show: (a). Lumen:total vessel diameter ratio in the ‘No MCT’, vehicle/‘MCT Only’, NTP42, Sildenafil, and Selexipag [n = 10, 13, 14, 12 and 6, respectively] in ‘No MCT’, MCT, NTP42, Sildenafil, and Selexipag, respectively); (b). Medial thickness [n = 10, 13, 13, 1 and 6, respectively], and (c). Degree of vessel occlusion [n = 10, 13, 14, 12 and 6, respectively] within all pulmonary arterioles (≥ 15 μm). Panels d-f. show: (d) Lumen:total vessel diameter ratio [n = 10, 9, 14, 12 and 6, respectively]; (e). Medial thickness [n = 10, 11, 14, 12 and 6, respectively], and (f). Degree of vessel occlusion [n = 10, 9, 14, 12 and 6, respectively] within small pulmonary arterioles only (≥ 15 μm, ≤ 50 μm). All data are expressed as the mean ± SEM. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001 vs. ‘MCT Only’, ^# P ≤ 0.05, ^## P ≤ 0.01 vs. NTP42, according to unpaired Student’s t tests. Note that the numbers (n) given in the square brackets refer to the number of input data used for the given parameter following removal of outliers identified using IQR with Tukey fences